VRDN
Viridian Therapeutics, Inc.\DE
NASDAQ · Healthcare · Biotechnology · US
$28.40
+12.92%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$28.27
From 52W high−15.93%
Volume6.49M
Market cap$3.22B
P/E (TTM)—
P/S (TTM)45.2x
Div yield—
Key dataNov 4, 2026
Open
$28.27
From 52W high
−15.93%
Volume
6.49M
Market cap
$3.22B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.0x
P/E (TTM)
—
RSI (14)
79.5
MomentumView details →
1D Return
+12.92%
YTD Return
−9.80%
SummaryUpdated Jun 1, 2026
Viridian Therapeutics, Inc. (NASDAQ:VRDN) is a clinical-stage biotechnology company founded in 2006 and headquartered in Waltham, Massachusetts. Originally established as Miragen Therapeutics, the company underwent a strategic transformation and rebranded to Viridian Therapeutics in January 2021. The company has evolved from its initial focus on microRNA-based therapeutics to become a specialized developer of antibody treatments targeting serious autoimmune and rare diseases, with particular emphasis on thyroid eye disease.
Similar companies
Latest newsMore news →
Viridian Therapeutics reported its Q2 2026 financial results, with total revenues of $284,000 and a net loss of $127.1 million.91d agoViridian Therapeutics received early FDA approval for Lumvoa, a treatment for thyroid eye disease.127d agoThe U.S. FDA approved Lumvoa (veligrotug-vvze) developed by Viridian Therapeutics for the treatment of thyroid eye disease.131d ago